SciNeuro Pharmaceuticals, a biotech company pioneering the development of novel treatments for neurodegenerative diseases, today announced the completion of a total of $53 million in equity financing. The round was led by LAV and ARCH Venture Partners with participation from new and existing investors.

神经科学制药公司（SciNeuro Pharmaceuticals）是一家致力于开发神经退行性疾病新型疗法的生物技术公司，今天宣布已完成总计5300万美元的股权融资。本轮融资由礼来亚洲基金（LAV）和ARCH Venture Partners领投，新投资者和现有投资者均有参与。

Together with a $5 million non-dilutive research grant recently awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), the proceeds will support the advancement of the company's pipeline of innovative therapeutics targeting a broad range of disease pathways including Lp-PLA21, beta amyloid and LRRK22 as well as the ongoing discovery of novel treatments for other CNS disorders..

加上最近由迈克尔·J. 福克斯帕金森研究基金会（MJFF）颁发的500万美元非稀释性研究资助，这些资金将用于推动公司创新治疗管线的发展，针对包括Lp-PLA21、β淀粉样蛋白和LRRK22在内的多种疾病通路，以及持续发现其他中枢神经系统疾病的新疗法。

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration - neurovascular inflammation, proteinopathy, and immune response.

SciNeuro Pharmaceuticals是一家临床阶段的生物技术公司，专注于开发针对神经退行性疾病的突破性疗法。自2020年成立以来，SciNeuro通过针对神经退行性疾病的三个关键驱动机制——神经血管炎症、蛋白病和免疫反应，构建了从发现到临床开发的多样化产品管线组合。

The company aims to develop disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other devastating CNS diseases..

公司旨在为阿尔茨海默病、帕金森病和其他破坏性的中枢神经系统疾病开发疾病修饰治疗方案。